Contributor Cindy H. Dubin interviews several leading companies and highlights trends in autoinjectors, pen injectors, wearable devices and connectivity, and prefilled syringes.
Jim Huang, PhD, says successful translation of discovery compounds into first-in-human and first-in-patient is one of the key challenges facing the pharmaceutical industry, and to achieve this, a rational formulation development strategy will be critical to avoid costly development failures, while speeding up the development timeline in a cost-effective manner.
DRUG DEVELOPMENT – Bringing New Drugs to Patients Faster by Integrating Traditionally Separate Pharma Development Functions
Nutan Gangrade, PhD, says reducing R&D project timelines saves on overhead in development while increasing the likelihood of primacy in the marketplace (which engenders significantly more sales) and describes new approaches drug developers are taking to streamline drug development.
Mark Behlke, MD, PhD, says gene editing raises legitimate questions and fears about possible risks and misuse, and given the relative technical ease and low cost of CRISPR gene editing, this is likely to find widespread use in both medicine and agriculture.
EXECUTIVE INTERVIEW – AMO Pharma: Identifying & Developing Cancer Pathway Therapeutic Candidates for Use in New Neurological Indications
Michael Snape, PhD, AMO Pharma’s Chief Scientific Officer, discusses the company’s research focus and efforts to understand and target the mechanism of action of CNS disorders associated with developmental delay with the potential to target neurogenetic disorders at their root cause.
John S. Vrettos, PhD, says numerous technologies are currently in development that are designed to enable the oral delivery of peptides. Though each has its unique set of properties and capabilities, all must overcome key obstacles to successfully deliver peptides via the oral route.
Tom McLean says combination drug development pipelines continue to rapidly expand and diversify with differentiated molecules and formulations, which can call for nuanced as well as significant packaging and delivery system requirements.
Nora Khaldi, PhD, Founder and Chief Executive Officer of Nuritas, discusses the company’s innovative approach to accelerating the discovery of novel therapeutic peptides that address unmet patient needs in multiple disease areas.
The global pharmaceutical analytical testing outsourcing market is expected to rise to an estimated value of $10.42 billion by 20261, up from $3.82 billion in…
2020 Respiratory Drug Development eBook – Inhaled Medications for Treating Unconventional Respiratory Diseases
This second annual Drug Development & Delivery Respiratory eBook focuses on a few companies that are taking inhalation devices to a new level in drug delivery.
EXCLUSIVE ONLINE CONTENT
CombiGene & Cobra Biologics Sign Agreement to Secure GMP Production of Plasmids for Production of Gene Therapy
Cobra Biologics and CombiGene AB (publ) (CombiGene) recently announced they have signed agreements covering Good Manufacturing Practice (GMP) production of two essential….
Gain Therapeutics, Inc. recently announced it has entered into a strategic research collaboration agreement with Sumitomo Dainippon Pharma Co., Ltd. for the research and development of….
Novus Therapeutics, Inc. recently announced it has completed the acquisition of Anelixis Therapeutics, Inc., a privately held clinical-stage biotechnology company developing a next-generation….
Vectura Partners With Monash University to Support Development of Inhaled Oxytocin to Prevent Postpartum Haemorrhage
Vectura Group plc recently announced it has signed an agreement with Monash University’s Institute of Pharmaceutical Sciences (MIPS) to develop inhaled oxytocin delivered via a….
Thermo Fisher Scientific recently announced new collaborations of the Thermo Fisher Precision Medicine Science Center (PMSC) with AstraZeneca and the University of Nebraska Medical Center as part of its ongoing development of….